Venus Remedies is currently trading at Rs 173.20, up by 2.40 points or 1.41% from its previous closing of Rs 170.80 on the BSE.
The scrip opened at Rs 162.35 and has touched a high and low of Rs 174.00 and Rs 162.30 respectively. So far 10812 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 358.05 on 15-May-2013 and a 52 week low of Rs 140.00 on 02-Aug-2013.
Last one week high and low of the scrip stood at Rs 202.00 and Rs 170.80 respectively. The current market cap of the company is Rs 193.37 crore.
The promoters holding in the company stood at 43.99% while Institutions and Non-Institutions held 9.95% and 46.06% respectively.
Venus Pharma GmbH, a subsidiary of Venus Remedies, has made big strides in the global market by bagging marketing authorisation (MA) approval from France for Meropenem, a generic broad spectrum antibiotic injectable. It has signed a non-exclusive marketing rights deal with generic giant Mylan to sell Meropenem in France world's fifth largest pharmaceutical market with a market share of 3.8%.
Driven by its MA grants, Venus is all set to grab the maximum share in the $270-million Meropenem market in the EU in the near future. Meropenem is an off-patented generic broad spectrum anti-bacterial agent of carbapenem family, which fights diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: